Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma Biotechnology's purchase of property, plant, equipment for the
three
months ended in Mar. 2026 was $0.0 Mil. It means Puma Biotechnology spent $0.0 Mil on purchasing property, plant, equipment.
Puma Biotechnology's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.0Mil.
Compared with last quarter ($0.0 Mil in Dec. 2025 ), Puma Biotechnology spent more money on purchasing property, plant, equipment in Mar. 2026 ($0.0 Mil).
Puma Biotechnology Purchase Of Property, Plant, Equipment Related Terms
Puma Biotechnology Purchase Of Property, Plant, Equipment Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's Purchase Of Property, Plant, Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Puma Biotechnology Purchase Of Property, Plant, Equipment Chart
Puma Biotechnology Purchase Of Property, Plant, Equipment Calculation
The amount used to purchase PPE.
Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Purchase Of Property, Plant, Equipment of $-0.0 Mil mean?
Puma Biotechnology (PBYI) has a Purchase Of Property, Plant, Equipment of $-0.0 Mil as of Mar. 2026. Purchase of PP&E is the total purchase of property, plant and equipment. View historical data for Puma Biotechnology and its competitors.
Is Puma Biotechnology's Purchase Of Property, Plant, Equipment too high?
Puma Biotechnology's current Purchase Of Property, Plant, Equipment is $-0.0 Mil. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Purchase Of Property, Plant, Equipment compare to EVMN and OCGN?
Puma Biotechnology's Purchase Of Property, Plant, Equipment of $-0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Purchase Of Property, Plant, Equipment for a Biotechnology company?
A good Purchase Of Property, Plant, Equipment depends on the Biotechnology industry context. However, Purchase Of Property, Plant, Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Purchase Of Property, Plant, Equipment mean?
A high Purchase Of Property, Plant, Equipment can signal that a stock is expensive relative to its fundamentals. Purchase of PP&E is the total purchase of property, plant and equipment. View historical data for Puma Biotechnology and its competitors. Puma Biotechnology's current Purchase Of Property, Plant, Equipment is $-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current Purchase Of Property, Plant, Equipment is $-0.0 Mil. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Purchase Of Property, Plant, Equipment calculated?
Purchase Of Property, Plant, Equipment is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Purchase Of Property, Plant, Equipment is $-0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Purchase Of Property, Plant, Equipment: $-0.0 Mil
GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
Purchase Of Property, Plant, Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
